Studies on the Metabolism of Troglitazone to Reactive Intermediates in Vitro and in Vivo. Evidence for Novel Biotransformation Pathways Involving Quinone Methide Formation and Thiazolidinedione Ring Scission
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Therapy with the oral antidiabetic agent troglitazone (Rezulin) has been associated with cases of severe hepatotoxicity and drug-induced liver failure, which led to the recent withdrawal of the product from the U.S. market. While the mechanism of this toxicity remains unknown, it is possible that chemically reactive metabolites of the drug play a causative role. In an effort to address this possibility, this study was undertaken to determine whether troglitazone undergoes metabolism in human liver microsomal preparations to electrophilic intermediates. Following incubation of troglitazone with human liver microsomes and with cDNA-expressed cytochrome P450 isoforms in the presence of glutathione (GSH), a total of five GSH conjugates (M1-M5) were detected and identified tentatively by LC-MS/MS analysis. In two cases (M1 and M5), the structures of the adducts were confirmed by NMR spectroscopy and/or by comparison with an authentic standard prepared by synthesis. The formation of GSH conjugates M1-M5 revealed the operation of two distinct metabolic activation pathways for troglitazone, one of which involves oxidation of the substituted chromane ring system to a reactive o-quinone methide derivative, while the second involves a novel oxidative cleavage of the thiazolidinedione (TZD) ring, potentially generating highly electrophilic alpha-ketoisocyanate and sulfenic acid intermediates. When troglitazone was administered orally to a rat, samples of bile were found to contain GSH conjugates which reflected the operation of these same metabolic pathways in vivo. The finding that metabolism of the TZD ring of troglitazone was catalyzed selectively by P450 3A enzymes is significant in light of the recent report that troglitazone is an inducer of this isoform in human hepatocytes. The implications of these results are discussed in the context of the potential for troglitazone to covalently modify hepatic proteins and to cause oxidative stress through redox cycling processes, either of which may play a role in drug-induced liver injury.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Mechanistic studies subsequently identified bioactivation by CYP3A4 and CYP2C8 to reactive quinone-like metabolites and ring-opened sulfenic acid intermediates that covalently bind cellular macromolecules and trigger mitochondrial injury, neither of which was reliably flagged by standard preclinical hepatotoxicity assays [75,76].”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [76]
In the citing paper
“Fialuridine (Section 7.1) and troglitazone (Section 7.4) are intrinsic toxicodynamic failures, driven by human-relevant mitochondrial injury and reactive-metabolite formation, respectively.”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [76]
In the citing paper
“Troglitazone, the first marketed thiazolidinedione, was withdrawn after reports of severe idiosyncratic hepatotoxicity, including fulminant liver failure and transplantation.”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [76]
In the citing paper
“even sophisticated PBPK or PBPK–PD models cannot reliably anticipate them without orthogonal mechanistic assays [69,70,75,76]”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [76]
In the citing paper
“Fourth, idiosyncratic toxicities, such as those underlying the fialuridine and troglitazone failures, are by definition not captured by any pharmacokinetic scaling framework, and even sophisticated PBPK or PBPK–PD models cannot reliably anticipate them without orthogonal mechanistic assays [69,70,75,76].”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [76]
Citations
Cites
Hepatic Dysfunction Associated with Troglitazone
Watkins, P. B., & Whitcomb, R. W. (1998) · New England Journal of Medicine · doi:10.1056/nejm199803263381314 · Cited by 446
Two Cases of Severe Clinical and Histologic Hepatotoxicity Associated with Troglitazone
Gitlin, N., Julie, N. L., Spurr, C. L., Lim, K. N., & Juarbe, H. M. (1998) · Annals of Internal Medicine · doi:10.7326/0003-4819-129-1-199807010-00008 · Cited by 230
Yoshioka, T., Fujita, T., Kanai, T., Aizawa, Y., Kurumada, T., Hasegawa, K., & Horikoshi, H. (1989) · Journal of Medicinal Chemistry · doi:10.1021/jm00122a022 · Cited by 221
Kohlroser, J., Mathai, J., Reichheld, J., Banner, B. F., & Bonkovsky, H. L. (2000) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2000.01707.x · Cited by 209
Troglitazone-Induced Hepatic Failure Leading to Liver Transplantation: A Case Report
Neuschwander-Tetri, B. A., Isley, W. L., Oki, J. C., Ramrakhiani, S., Quiason, S. G., Phillips, N. J., & Brunt, E. M. (1998) · Annals of Internal Medicine · doi:10.7326/0003-4819-129-1-199807010-00009 · Cited by 195
Kassahun, K., Hu, P. L., Grillo, M. P., Davis, M. R., Jin, L., & Baillie, T. A. (1994) · Chemico-Biological Interactions · doi:10.1016/0009-2797(94)90014-0 · Cited by 74
Self-citationOhe, T., Mashino, T., & Hirobe, M. (1994) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.1994.1185 · Cited by 64
Davis, M. R., Kassahun, K., Jochheim, C. M., Brandt, K. M., & Baillie, T. A. (1993) · Chemical Research in Toxicology · doi:10.1021/tx00033a020 · Cited by 44
Self-citation
Research works printed but not linked: 16
- Henry R. R., 1997, Thiazolidinones. Curr. Ther. Diabetes 26, 553−573
- Hu J., 1999, J. Org. Chem., 64
- Hart T. W., 1985, Tetrahedron Lett., 26
- Baillie T. A., 1993, Mass spectrometry in the analysis of glutathione conjugates. Biol. Mass Spectrom. 22, 319−325
- Kassahun K., 1997, Biotransformation of the naturally occurring isothiocyanate sulforaphane in the rat: Identification of Phase I metabolites and glutathione conjugates. Chem. Res. Toxicol. 10, 1228−1233
- Borel A. G., 1993, Identification of carbomoylated thiol conjugates as metabolites of the antineoplastic 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea, in rats and humans. Drug Metab. Dispos. 21, 889−901
- Kawai K., 1997, Disposition and metabolism of the new oral antidiabetic drug troglitazone in rats, mice and dogs. Arzneim.-Forsch. 47, 356−368
- Loi C. M., 1997, J. Clin. Pharmacol., 37
- Ohe T., 1997, Substituent elimination from p-substituted phenols by cytochrome P450. ipso-Substitution by the oxygen atom of the active species. Drug Metab. Dispos. 25, 116−122
- Ohe T., 2000, Novel metabolic pathway of estrone and 17β-estradiol catalyzed by cytochrome P-450. Drug Metab. Dispos. 28, 110−112
- Yamazaki H., 1999, Oxidation of troglitazone to a quinone-type metabolite catalyzed by cytochrome P-450 2C8 and P-450 3A4 in human liver microsomes. Drug Metab. Dispos. 27, 1260−1266
- He K., 1999, Proceedings of the 9th North American ISSX Meeting, #207
- Polsker G. L., 1999, Troglitazone. A review of its use in the management of type 2 diabetes mellitus. Drugs 57, 409−438
- Ramachandran V., 1999, Troglitazone increases cytochrome P-450 3A protein and activity in primary cultures of human hepatocytes. Drug Metab. Dispos. 27, 1194−1199
- Mansuy D., 1991, J. Am. Chem. Soc., 113
- Abbreviations TZD, thiazolidinedione
Cited by
Cytochrome P450 and Chemical Toxicology
Guengerich, F. P. (2008) · Chemical Research in Toxicology · doi:10.1021/tx700079z · Cited by 1,725
Summary of information on human CYP enzymes: human P450 metabolism data
Rendic, S. (2002) · Drug Metabolism Reviews · doi:10.1081/dmr-120001392 · Cited by 820
Evans, D. C., Watt, A. P., Nicoll-Griffith, D. A., & Baillie, T. A. (2004) · Chemical Research in Toxicology · doi:10.1021/tx034170b · Cited by 706
Self-citationStepan, A. F., Walker, D. P., Bauman, J., Price, D. A., Baillie, T. A., Kalgutkar, A. S., & Aleo, M. D. (2011) · Chemical Research in Toxicology · doi:10.1021/tx200168d · Cited by 698
Self-citationo-Quinone methides: intermediates underdeveloped and underutilized in organic synthesis
Water, R. W. V. D., & Pettus, T. R. R. (2002) · Tetrahedron · doi:10.1016/s0040-4020(02)00496-9 · Cited by 587
THE ROLE OF METABOLIC ACTIVATION IN DRUG-INDUCED HEPATOTOXICITY
Park, B. K., Kitteringham, N. R., Maggs, J. L., Pirmohamed, M., & Williams, D. P. (2005) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.45.120403.100058 · Cited by 453
Complex reactions catalyzed by cytochrome P450 enzymes
Isin, E. M., & Guengerich, F. P. (2007) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2006.07.003 · Cited by 448
Mechanisms of Drug Toxicity and Relevance to Pharmaceutical Development
Guengerich, F. P. (2011) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.dmpk-10-rv-062 · Cited by 387
Elucidating mechanisms of drug-induced toxicity
Liebler, D. C., & Guengerich, F. P. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1720 · Cited by 323
“This drug is known to be converted into reactive species that generate a relatively high level of covalent bindin”
BackgroundRole of Metabolism in Drug-Induced Idiosyncratic Hepatotoxicity
Walgren, J. L., Mitchell, M. D., & Thompson, D. C. (2005) · Critical Reviews in Toxicology · doi:10.1080/10408440590935620 · Cited by 322
“The formation of five glutathione adducts during incubations of troglitazone with human liver microsomes was recently reported by Kassahun et al. (2001).”
BackgroundCentral role of mitochondria in drug-induced liver injury
Pessayre, D., Fromenty, B., Berson, A., Robin, M.-A., Lettéron, P., Moreau, R., & Mansouri, A. (2012) · Drug Metabolism Reviews · doi:10.3109/03602532.2011.604086 · Cited by 277
“One possible mechanism is CYP-mediated metabolic activation (Kassahun et al., 2001), whereas another involves mitochondrial proapoptotic effects.”
BackgroundDrug Bioactivation Covalent Binding to Target Proteins and Toxicity Relevance
Zhou, S., Chan, E., Duan, W., Huang, M., & Chen, Y.-Z. (2005) · Drug Metabolism Reviews · doi:10.1081/dmr-200028812 · Cited by 274
Inhibition of Cytochrome P450 Enzymes
Correia, M. A., & Hollenberg, P. F. (2015) · Cytochrome P450 · doi:10.1007/978-3-319-12108-6_5 · Cited by 257
Mechanisms of cytochrome P450 substrate oxidation: MiniReview
Guengerich, F. P. (2007) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.20174 · Cited by 249
“An example of a bioactivation of a drug (troglitazone) to electrophilic products tagged by glutathione (GSH) [38,39].”
Background3D Organotypic Cultures of Human HepaRG Cells: A Tool for In Vitro Toxicity Studies
Gunness, P., Mueller, D., Shevchenko, V., Heinzle, E., Ingelman-Sundberg, M., & Noor, F. (2013) · Toxicological Sciences · doi:10.1093/toxsci/kft021 · Cited by 236
Applying Mechanisms of Chemical Toxicity to Predict Drug Safety
Guengerich, F. P., & MacDonald, J. S. (2007) · Chemical Research in Toxicology · doi:10.1021/tx600260a · Cited by 231
Minimising the potential for metabolic activation in drug discovery
Kalgutkar, A. S., & Soglia, J. R. (2005) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.1.1.91 · Cited by 229
“(2005) 1(1) 115 Thiazolidinediones P450-catalysed GSH trapping of electrophilic S-oxides and cyanate species in LM as shown below [53]”
BackgroundNegative Ion Tandem Mass Spectrometry for the Detection of Glutathione Conjugates
Dieckhaus, C. M., Fernández-Metzler, C. L., King, R., Krolikowski, P. H., & Baillie, T. A. (2005) · Chemical Research in Toxicology · doi:10.1021/tx049741u · Cited by 220
Self-citationKirchheiner, J., Roots, I., Goldammer, M., Rosenkranz, B., & Brockm??ller, J. (2005) · Clinical Pharmacokinetics · doi:10.2165/00003088-200544120-00002 · Cited by 204
Mechanisms of Troglitazone Hepatotoxicity
Smith, M. T. (2003) · Chemical Research in Toxicology · doi:10.1021/tx034033e · Cited by 197
Troglitazone-induced liver failure: a case study
Graham, D. J., Green, L., Senior, J. R., & Nourjah, P. (2003) · The American Journal of Medicine · doi:10.1016/s0002-9343(02)01529-2 · Cited by 186
Li, A. P. (2002) · Chemico-Biological Interactions · doi:10.1016/s0009-2797(02)00051-0 · Cited by 181
Gan, J., Harper, T. W., Hsueh, M.-M., Qu, Q., & Humphreys, W. G. (2005) · Chemical Research in Toxicology · doi:10.1021/tx0496791 · Cited by 178
Ong, M. M. K., Latchoumycandane, C., & Boelsterli, U. A. (2007) · Toxicological Sciences · doi:10.1093/toxsci/kfl180 · Cited by 178
“…from oxidant stress directly generated in mitochondria or as a consequence of cytosolic oxidant stress generated from troglitazone metabo- lism, e.g., from thiol-reactive intermediates including the activated thiazolidinedione ring (He et al., 2001; Kassahun et al., 2001; Tettey et al., 2001).”
BackgroundWatanabe, I., Tomita, A., Shimizu, M., Sugawara, M., Yasumo, H., Koishi, R., Takahashi, T., Miyoshi, K., Nakamura, K., Izumi, T., et al. (2003) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(03)00014-6 · Cited by 174
“Control 25 (29) 27 (32) 20 (24) 13 (15) 85 (100) 7.”
Hollenberg, P. F., Kent, U. M., & Bumpus, N. N. (2008) · Chemical Research in Toxicology · doi:10.1021/tx7002504 · Cited by 167
Thiazolidine-2,4-diones: Progress towards multifarious applications
Jain, V. S., Vora, D. K., & Ramaa, C. S. (2013) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2013.01.029 · Cited by 165
Designing around Structural Alerts in Drug Discovery
Kalgutkar, A. S. S. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00917 · Cited by 174
How safe is the use of thiazolidinediones in clinical practice?
Rizos, C., Elisaf, M., Mikhailidis, D., & Liberopoulos, E. (2009) · Expert Opinion on Drug Safety · doi:10.1517/14740330802597821 · Cited by 161
“Troglitazone may induce liver enzymes that catalyze troglitazone biotransformation to chemically reactive intermediates, which in turn could promote liver injury [83] .”
BackgroundA history of the roles of cytochrome P450 enzymes in the toxicity of drugs
Guengerich, F. P. (2020) · Toxicological Research · doi:10.1007/s43188-020-00056-z · Cited by 159
Mitochondrial Involvement in Drug-Induced Liver Injury
Pessayre, D., Mansouri, A., Berson, A., & Fromenty, B. (2009) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-00663-0_11 · Cited by 154
Hepatotoxicity with Thiazolidinediones: Is it a Class Effect?
Scheen, A. J. (2001) · Drug Safety · doi:10.2165/00002018-200124120-00002 · Cited by 151
“[97] Use of hepatocyte cultures may be helpful for studying the hepatotoxicity of compounds.”
BackgroundBiochemical mechanisms in drug-induced liver injury: Certainties and doubts
Grattagliano, I., Bonfrate, L., Diogo, C. V., Wang, H. H., Wang, D. Q., & Portincasa, P. (2009) · World Journal of Gastroenterology · doi:10.3748/wjg.15.4865 · Cited by 136
Testa, B., & Krämer, S. D. (2008) · Chemistry & Biodiversity · doi:10.1002/cbdv.200890199 · Cited by 164
A critical perspective on 3D liver models for drug metabolism and toxicology studies
Serras, A. S., Rodrigues, J. S., Cipriano, M., Rodrigues, A. V., Oliveira, N. G., & Miranda, J. P. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.626805 · Cited by 138
Holt, M., & Ju, C. (2010) · Handbook of Experimental Pharmacology · doi:10.1007/978-3-642-00663-0_1 · Cited by 129
The Antifungal Activity of Naphthoquinones: An Integrative Review
Futuro, D. O., Ferreira, P. G., Nicoletti, C. D., Borba-Santos, L. P., da Silva, F. D. C., Rozental, S., & Ferreira, V. F. (2018) · Anais da Academia Brasileira de Ciências · doi:10.1590/0001-3765201820170815 · Cited by 142
Bae, M., & Song, B. J. (2003) · Molecular Pharmacology · doi:10.1124/mol.63.2.401 · Cited by 143
“, 1999) or TRO ring scission pathway (Kassahun et al., 2001), before conjugation with glutathione.”
BackgroundMetabolic and Non-Metabolic Factors Determining Troglitazone Hepatotoxicity: A Review
Masubuchi, Y. (2006) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.21.347 · Cited by 132
A Predictive Ligand-Based Bayesian Model for Human Drug-Induced Liver Injury
Ekins, S., Williams, A. J., & Xu, J. J. (2010) · Drug Metabolism and Disposition · doi:10.1124/dmd.110.035113 · Cited by 122
“…with high Bayesian scores and present in many DILI compounds, appeared to be reactive in nature which could cause time dependent inhibition of CYPs for example (Zientek et al., 2010) or be precursors for metabolites (Kassahun et al., 2001) that are reactive and may covalently bind to proteins.”
BackgroundYan, Z., & Caldwell, G. W. (2004) · Analytical Chemistry · doi:10.1021/ac040159k · Cited by 134
Shaw, P. J., Ganey, P. E., & Roth, R. A. (2010) · Toxicological Sciences · doi:10.1093/toxsci/kfq168 · Cited by 123
“TGZ is metabolized in the rat to five intermediates with the ability to form glutathione conjugates that appear in bile (Kassahun et al., 2001).”
BackgroundMasubuchi, N., Makino, C., & Murayama, N. (2007) · Chemical Research in Toxicology · doi:10.1021/tx060234h · Cited by 123
Designing Drugs to Avoid Toxicity
Smith, G. F. (2011) · Progress in medicinal chemistry · doi:10.1016/b978-0-12-381290-2.00001-x · Cited by 137
Metabolic activation in drug-induced liver injury
Leung, L., Kalgutkar, A. S., & Obach, R. S. (2012) · Drug Metabolism Reviews · doi:10.3109/03602532.2011.605791 · Cited by 118
“As noted earlier, both the chromane and thiazolidenedione ring systems in troglitazone succumb to CYP3A4-catalyzed bioactivation to reactive metabolites (Kassahun et al., 2001; He et al., 2004).”
BackgroundRodgers, A. D., Zhu, H., Fourches, D., Rusyn, I., & Tropsha, A. (2010) · Chemical Research in Toxicology · doi:10.1021/tx900451r · Cited by 115
Cellular Responses to the Metal-Binding Properties of Metformin
Logie, L., Harthill, J., Patel, K., Bacon, S., Hamilton, D. L., Macrae, K., McDougall, G., Wang, H.-H., Xue, L., Jiang, H., et al. (2012) · Diabetes · doi:10.2337/db11-0961 · Cited by 108
“This part of the molecule becomes linearized in vivo by oxidation of the sulfur atom (36), substitution of which results in compounds with reduced antihyperglycemic efficacy (37); however, further work will be required to determine whether or not these structural similarities contribute toward the common effects of pi…”
BackgroundHe, K., Talaat, R. E., Pool, W. F., Reily, M. D., Reed, J. E., Bridges, A. J., & Woolf, T. F. (2004) · Drug Metabolism and Disposition · doi:10.1124/dmd.32.6.639 · Cited by 115
“Recently, Kassahun et al. (2001) reported five glutathione (GSH) conjugates of 1 Current address: DSM-BT, S3216, Wyeth Research, 500 Arcola Road, Collegeville, PA 19426.”
BackgroundComparative effects of thiazolidinediones on in vitro P450 enzyme induction and inhibition
Sahi, J., Black, C. B., Hamilton, G. A., Zheng, X., Jolley, S., Rose, K. A., Gilbert, D., LeCluyse, E. L., & Sinz, M. W. (2003) · Drug Metabolism and Disposition · doi:10.1124/dmd.31.4.439 · Cited by 113
“In addition, Kassahun et al., 2001 determined that troglitazone was a NADPH- and time-dependent inhibitor in human liver microsomes, indicating a combination of irreversible and reversible mechanisms of inhibition.”
BackgroundNiessen, W. M. A. (2011) · Mass Spectrometry Reviews · doi:10.1002/mas.20332 · Cited by 111
Castro‐Perez, J. M., Plumb, R. S., Liang, L., & Yang, E. (2005) · Rapid Communications in Mass Spectrometry · doi:10.1002/rcm.1855 · Cited by 118
Effects of Troglitazone on HepG2 Viability and Mitochondrial Function
Tirmenstein, M. A. (2002) · Toxicological Sciences · doi:10.1093/toxsci/69.1.131 · Cited by 110
“(1993) concluded that CYP3A7 was exclusively expressed in HepG2 cells.”
BackgroundInfluentialProgress in computational toxicology
Ekins, S. (2013) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/j.vascn.2013.12.003 · Cited by 108
Kalgutkar, A. S. S., & Didiuk, M. T. (2009) · Chemistry & Biodiversity · doi:10.1002/cbdv.200900055 · Cited by 107
Long-Term Chronic Toxicity Testing Using Human Pluripotent Stem Cell–Derived Hepatocytes
Holmgren, G., Sjogren, A.-K. M., Barragán, I., Sabirsh, A., Sartipy, P., Synnergren, J., Björquist, P., Ingelman‐Sundberg, M., Andersson, T. B., & Edsbagge, J. (2014) · Drug Metabolism and Disposition · doi:10.1124/dmd.114.059154 · Cited by 102
Masubuchi, Y., Kano, S., & Horie, T. (2006) · Toxicology · doi:10.1016/j.tox.2006.02.017 · Cited by 100
Gan, J., Ruan, Q., He, B., Zhu, M., Shyu, W. C., & Humphreys, W. G. (2009) · Chemical Research in Toxicology · doi:10.1021/tx800368n · Cited by 102
Soglia, J. R., Contillo, L. G., Kalgutkar, A. S. S., Zhao, S. X., Hop, C. E. C. A., Boyd, J. G., & Cole, M. J. (2006) · Chemical Research in Toxicology · doi:10.1021/tx050303c · Cited by 96
Enzyme-Induction Dependent Bioactivation of Troglitazone and Troglitazone Quinone In Vivo
Tettey, J. N. A., Maggs, J. L., Rapeport, G., Pirmohamed, M., & Park, B. K. (2001) · Chemical Research in Toxicology · doi:10.1021/tx0001981 · Cited by 96
Alvarez‐Sánchez, R., Montavon, F., Härtung, T., & Pähler, A. (2006) · Chemical Research in Toxicology · doi:10.1021/tx050353h · Cited by 96
Toxicological Significance of Mechanism-Based Inactivation of Cytochrome P450 Enzymes by Drugs
Masubuchi, Y., & Horie, T. (2007) · Critical Reviews in Toxicology · doi:10.1080/10408440701215233 · Cited by 95
“…that reactive metabolites formed from oxidative cleavage of the common thiazolidinedione ring and/or a quinone methide formed from the troglitazone-specific chromane moiety, both of which have been identified as their GSH adducts (Kassahun et al., 2001), are involved in the inactivation of CYP3A4.”
BackgroundDrug-Induced Liver Injury: Insights from Genetic Studies
Andrade, R. J., Robles, M., Ulzurrun, E., & Lucena, M. I. (2009) · Pharmacogenomics · doi:10.2217/pgs.09.111 · Cited by 94
Quinone Methide Bioactivation Pathway: Contribution to Toxicity and/or Cytoprotection?
Bolton, J. L. (2014) · Current Organic Chemistry · doi:10.2174/138527281801140121123046 · Cited by 90
“o-Quinone methide formation as shown in Scheme 4 could contribute to the hepatotoxic effects of troglitazone [7, 31].”
BackgroundPeroxidases: a role in the metabolism and side effects of drugs
Tafazoli, S., & O'Brien, P. J. (2005) · Drug Discovery Today · doi:10.1016/s1359-6446(05)03394-5 · Cited by 97
Rendic, S. P., & Guengerich, F. P. (2021) · Archives of Toxicology · doi:10.1007/s00204-020-02971-4 · Cited by 88
Do Preclinical Testing Strategies Help Predict Human Hepatotoxic Potentials?
Peters, T. S. (2005) · Toxicologic Pathology · doi:10.1080/01926230590522121 · Cited by 86
Nassar, A.-E. F., Kamel, A. M., & Clarimont, C. (2004) · Drug Discovery Today · doi:10.1016/s1359-6446(04)03297-0 · Cited by 96
A gene expression signature for oxidant stress/reactive metabolites in rat liver
McMillian, M., Nie, A. Y., Parker, J. B., Leone, A. M., Bryant, S., Kemmerer, M., Herlich, J., Liu, Y., Yieh, L., Bittner, A., et al. (2004) · Biochemical Pharmacology · doi:10.1016/j.bcp.2004.08.003 · Cited by 85
“Previously our group has characterized 24 h liver transcriptional responses to macrophage activators and peroxisome proliferators [38], two classes of compounds reported to be oxidative stressors in the liver [25,36,37,39].”
InfluentialLim, H., Duczak, N., Brougham, L. R., Elliot, M., Patel, K., & Chan, K. (2005) · Drug Metabolism and Disposition · doi:10.1124/dmd.104.003475 · Cited by 84
“For example, the three glitazones (troglitazone, rosiglitazone and pioglitazone) are able to generate reactive metabolites from oxidation of chromane and/or 2,4-thiazolidinedione moieties (Kassahun et al., 2001).”
BackgroundFormation of a Novel Quinone Epoxide Metabolite of Troglitazone with Cytotoxic to HepG2 Cells
Yamamoto, Y., Yamazaki, H., Ikeda, T., Watanabe, T., Iwabuchi, H., Nakajima, M., & Yokoi, T. (2002) · Drug Metabolism and Disposition · doi:10.1124/dmd.30.2.155 · Cited by 84
Troglitazone induces a rapid drop of mitochondrial membrane potential in liver HepG2 cells
Bova, M. P., Tam, D., McMahon, G., & Mattson, M. N. (2004) · Toxicology Letters · doi:10.1016/j.toxlet.2004.08.009 · Cited by 83
Gunning, V., Tzafestas, K., Sparrow, H., Johnston, E. J., Brentnall, A. S., Potts, J. R., Rylott, E. L., & Bruce, N. C. (2014) · PLANT PHYSIOLOGY · doi:10.1104/pp.114.237180 · Cited by 88
“While this has been observed previously in GST conjugation to methyl-substituted aromatic rings (Kassahun et al., 2001; Li et al., 2009), this is, to our knowledge, the first report of such a GST conjugate to TNT.”
BackgroundIn silico models for drug-induced liver injury – current status
Przybylak, K. R., & Cronin, M. T. (2012) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2012.648613 · Cited by 82
“Moreover, drug metabolism in the liver leads to bioactivation to toxic (reactive) intermediates which, in turn, can adversely affect the structure and the function of the liver [8-11].”
BackgroundDrug metabolite profiling and elucidation of drug-induced hepatotoxicity
Tang, W. (2007) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.3.3.407 · Cited by 90
“A reactive o-quinone methide was implicated in the former reaction, whereas α-ketoisocyanate and sulfenic acid intermediates were in the latter [52].”
BackgroundSelf-citationTang, W., & Lu, A. Y. H. (2009) · Drug Metabolism Reviews · doi:10.3109/03602530903401658 · Cited by 80
“Studies of troglitazone metabolism led to the identification of several reactive intermediates, all of which result from P450-catalyzed oxidation of either the hydroxy chromane or the thiazolidinedione moiety (Yamazaki et al., 1999; Kassahun et al., 2001).”
BackgroundSelf-citationZhang, H., Ma, L. M., He, K., & Zhu, M. (2008) · Journal of Mass Spectrometry · doi:10.1002/jms.1432 · Cited by 78
Gustafsson, F., Foster, A. J., Sarda, S., Bridgland-Taylor, M. H., & Kenna, J. G. (2014) · Toxicological Sciences · doi:10.1093/toxsci/kft223 · Cited by 77
Xie, C., Zhong, D., & Chen, X. (2013) · Analytica Chimica Acta · doi:10.1016/j.aca.2013.06.022 · Cited by 77
Birringer, M., Siems, K., Maxones, A., Frank, J., & Lorkowski, S. (2018) · RSC Advances · doi:10.1039/c7ra11819h · Cited by 76
Toxicophores: Investigations in drug safety
Williams, D. P. (2006) · Toxicology · doi:10.1016/j.tox.2006.05.101 · Cited by 78
“The protein signals and cross-talk pathways that activate and recruit NK/NK T cells to the liver in the early stages of APAP hepatotoxicity are currently unknown ( Kaplowitz, 2005 ).”
BackgroundInfluentialLong, N., Gresley, A. L., & Wren, S. P. (2021) · ChemMedChem · doi:10.1002/cmdc.202100177 · Cited by 71
Yang, X., Schnackenberg, L. K., Shi, Q., & Salminen, W. F. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-404630-6.00013-0 · Cited by 71
Inhibition of Cytochrome P450 Enzymes
Correia, M. A., & de Montellano, P. R. O. (2007) · Springer eBooks · doi:10.1007/0-387-27447-2_7 · Cited by 72
Mechanisms and Outcomes of Drug- and Toxicant-Induced Liver Toxicity in Diabetes
Wang, T., Shankar, K., Ronis, M. J. J., & Mehendale, H. M. (2007) · Critical Reviews in Toxicology · doi:10.1080/10408440701215100 · Cited by 73
“Using both in vitro and in vivo approaches, Kassahun et al. (2001) revealed that troglitazone undergoes biotransformation in the liver to reactive metabolites, an o-quinone methide derivative, and possibly α-ketoisocyanate and sulfenic acid intermediates, which may form covalent adducts to hepatic…”
BackgroundZamek‐Gliszczynski, M. J., Chu, X., Polli, J. W., Paine, M. F., & Galetin, A. (2013) · Drug Metabolism and Disposition · doi:10.1124/dmd.113.055558 · Cited by 70
“In addition, other mechanisms besides transporter inhibition may contribute to the toxicity of troglitazone (Kassahun et al., 2001).”
BackgroundHaskins, J. R., Rowse, P. E., Rahbari, R., & de la Iglesia, F. (2001) · Archives of Toxicology · doi:10.1007/s002040100251 · Cited by 66
Yan, Z., Maher, N., Torres, R., Caldwell, G. W., & Huebert, N. D. (2005) · Rapid Communications in Mass Spectrometry · doi:10.1002/rcm.2195 · Cited by 64
Narayanan, P. K., Hart, T., Elcock, F. J., Zhang, C., Hahn, L., McFarland, D., Schwartz, L. W., Morgan, D., & Bugelski, P. J. (2003) · Cytometry Part A · doi:10.1002/cyto.a.10011 · Cited by 65
“one-electron oxidation of the chromane moiety (1,5,6) to”
BackgroundResultHonma, W., Shimada, M., Sasano, H., Ozawa, S., Miyata, M., Nagata, K., Ikeda, T., & Yamazoe, Y. (2002) · Drug Metabolism and Disposition · doi:10.1124/dmd.30.8.944 · Cited by 59
Identification of glutathione conjugates of troglitazone in human hepatocytes
Prabhu, S., Fackett, A., Lloyd, S., McClellan, H., Terrell, C. M., Silber, P. M., & Li, A. P. (2002) · Chemico-Biological Interactions · doi:10.1016/s0009-2797(02)00056-x · Cited by 59
Prediction models for drug-induced hepatotoxicity by using weighted molecular fingerprints
Kim, E., & Nam, H. (2017) · BMC Bioinformatics · doi:10.1186/s12859-017-1638-4 · Cited by 58
“When those drugs are taken and reached to liver, the drugs can be toxic in human bodies when metabolites are involved converting them to be highly reactive and causing organ damages [12; 17; 22].”
BackgroundLi, H., Huang, W. H., Qiu, B., Thabet, H. K., Alhashmialameer, D., Huang, M., & Guo, Z. (2022) · Advanced Composites and Hybrid Materials · doi:10.1007/s42114-022-00508-0 · Cited by 57
“The characteristic peaks located at 1490 and 1568 cm−1 correspond to the C = C stretching vibration of benzene ring and quinone ring of PANI [34, 35].”
BackgroundDeng, Y., Madatian, A., Wire, M. B., Bowen, C. J., Park, J. W., Williams, D. D., Peng, B., Schubert, E. M., Gorycki, F., Levy, M. A., et al. (2011) · Drug Metabolism and Disposition · doi:10.1124/dmd.111.040170 · Cited by 57
“The formation of methides has been reported as a bioactivation pathway for a number of drugs, although quinone methides are more typically involved (Bolton et al., 1990; Fan and Bolton, 2001; Kassahun et al., 2001; Zhang et al., 2003; Yan et al., 2005).”
BackgroundThe primary role of hepatic metabolism in idiosyncratic drug-induced liver injury
Amacher, D. E. (2012) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2012.658041 · Cited by 55
Yokoi, T. (2009) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-00663-0_14 · Cited by 55
Woodhead, J. L., Watkins, P. B., Howell, B. A., Siler, S. Q., & Shoda, L. K. M. (2016) · Drug Metabolism and Pharmacokinetics · doi:10.1016/j.dmpk.2016.11.008 · Cited by 54
Tilekar, K. N., Shelke, O., Upadhyay, N., Lavecchia, A., & Ramaa, C. S. (2021) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2021.131767 · Cited by 57
Pessayre, D., & Larrey, D. G. (2007) · Wiley eBooks · doi:10.1002/9780470691861.ch14a · Cited by 55
Lee, Y. H., Chung, M. C. M., Lin, Q., & Boelsterli, U. A. (2008) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2008.03.025 · Cited by 55
“related to the drug's toxicity (Kassahun et al., 2001; Tettey et al., 2001; He et al., 2004), mitochondrial toxicity has also been identified as a hazard.”
BackgroundClaesson, A., & Minidis, A. B. E. (2018) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.8b00046 · Cited by 53
Metadata
- Authors
- Kassahun, K., Pearson, P. G., Tang, W., McIntosh, I., Leung, K., Elmore, C., Dean, D., Wang, R., Doss, G., & Baillie, T. A.
- Affiliations
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Corresponding author
- Kassahun, Kelem
- Venue
- Chemical Research in Toxicology
- Publisher
- American Chemical Society (ACS)
- Published
- 2000-12-08
- Volume
- 14
- Issue
- 1
- Pages
- 62-70
- ISSN
- 0893-228X (ISSN-L)
- 1520-5010
- OpenAlex
- W2068532562
- Cited by
- 311
- References
- 8
- Citations by year
- 2026: 2 · 2025: 4 · 2024: 6 · 2023: 7 · 2022: 9 · 2021: 10 · 2020: 5 · 2019: 4 · 2018: 10 · 2017: 8 · 2016: 8 · 2015: 9 · 2014: 15 · 2013: 12 · 2012: 16
- FWCI
- 9.82
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Chemical Research in Toxicology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Bioactive Compounds and Antitumor Agents
- Keywords
- troglitazone, drug metabolism, reactive metabolites, glutathione conjugates, CYP3A, hepatotoxicity, drug-induced liver injury, sulfenic acid, oxidative stress, redox cycling, covalent protein modification, human liver microsomes, bile
- MeSH terms
- Troglitazone, Animals, Bile, Biotransformation, Catalysis, Chromans, Chromatography, Liquid, Cytochrome P-450 Enzyme System, Glutathione, Humans, Hypoglycemic Agents, Isoenzymes, Ketoconazole, Kinetics, Microsomes, Liver, NADP, Mass Spectrometry, Steroid Hydroxylases, Thiazoles, Thiazolidinediones, Rats, Cytochrome P-450 Enzyme Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.